FRANKFURT AM MAIN – With rapid advancements in medical research, technology, and increasing global demand for healthcare, the pharmaceutical industry is expected to experience substantial growth in the coming years. The COVID-19 pandemic has highlighted the crucial role of pharmaceutical companies in developing vaccines and therapeutics, driving investments and innovation in the sector. Additionally, the aging population and the prevalence of chronic diseases continue to drive the demand for innovative drugs and treatments. According to Evaluate Pharma, prescription drug sales are forecast to grow at an annualized 5.9% between 2023 and 2028, growing from $ 1 118bn to $1 580bn”. Envisaging this potential, Solactive leveraged its open architecture approach and partnered with Evaluate, a Norstella company, to launch the Solactive Evaluate Global Pharma Index.
The Solactive Evaluate Global Pharma Index is a representation of securities with potential future revenues in the pharmaceutical industry. To be eligible for inclusion in the index, a company’s total estimated future 5-year revenues must exceed $ 1,000,000 and be derived from products and services in the following therapeutic areas: blood, cancer, cardiovascular, diabetes, gastrointestinal, hepatic & biliary, HIV & related conditions, hormone, immunology, infections, miscellaneous, musculoskeletal, neurology, psychiatry, oncology, reproduction, respiratory, sensory organs, skin, surgery, and urinary tract.
Timo Pfeiffer, Chief Markets Officer at Solactive, said: “We are thrilled to partner with Evaluate to launch the Solactive Evaluate Global Pharma Index, our first co-branded index with them in a sector that plays a crucial role in advancing healthcare and addressing global health challenges. This collaboration brings together Solactive‘s open architecture approach and Evaluate’s expertise in pharmaceutical insight, enabling us to provide an index with a comprehensive representation of securities in the pharmaceutical industry. We look forward to continuing our successful partnership and developing innovative solutions for the investment community.”
Kevin Morgan, Chief Data Operations Officer at Evaluate, said: “The importance of high-quality insight and forecasting in the pharmaceutical industry is critical for successful investments. By combining the capabilities and expertise of Evaluate and Solactive, this new index will enable the investment and trading community to benchmark key areas of growth, emerging pharmaceutical technologies, and clinical innovations that will enable them to make effective investment decisions.”
For more information, please visit:
https://www.solactive.com/
About Solactive
Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.
The unique blend of our 300 staff’s expertise in data, data science, financial markets, and technology enables our clients’ continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 26,000 indices calculated daily, we offer a full suite of solutions, including market leading ESG and thematic indices.
As at January 2023, Solactive served approximately 500 clients across the world, with approximately US$250 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.
About Evaluate Ltd
Since 1996, Evaluate, a Norstella company, has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary and industry data into their workflows, tools and processes so they can work more effectively and efficiently. For more information about Evaluate, visit https://www.evaluate.com and follow us on LinkedIn and Twitter.
About Norstella
Norstella consists of several prominent pharmaceutical solutions providers—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group. United by a shared mission, to help patients gain access to life-saving therapies. Norstella offers comprehensive insights throughout the drug development lifecycle, leveraging unparalleled data, cutting-edge technology, and expert insights and consultancy. For more information, visit Norstella and follow on LinkedIn.
